New vaccine combo aims to stop pancreatic cancer return after surgery

NCT ID NCT06353646

Recruiting now Disease control Sponsor: Wu Wenming Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a personalized cancer vaccine (XH001) given after surgery for pancreatic cancer, followed by immunotherapy drugs (ipilimumab, sintilimab) and chemotherapy (gemcitabine + capecitabine). The goal is to see if this combination can prevent the cancer from coming back. The trial will enroll 28 adults who have had their tumor completely or nearly completely removed and have not had prior treatment. Researchers will track how long patients stay cancer-free and monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XH001 (neoantigen cancer vaccine), ipilimumab, sintilimab, gemcitabine, capecitabine
What this could lead to: If it works, this combination could help prevent pancreatic cancer from coming back after surgery, potentially extending survival.
What could go wrong: This is a very small, early-phase trial with only 28 people, so results may not apply broadly. The treatment involves multiple drugs with significant side effects, and the vaccine is experimental.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.